Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Inovio Pharmaceuticals (NASDAQ:INO) but lowers the price target from $40 to $33.
August 12, 2024 | 1:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst Jay Olson maintains an Outperform rating on Inovio Pharmaceuticals but lowers the price target from $40 to $33.
The Outperform rating suggests a positive outlook, but the lowered price target indicates tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100